Setting up a registry.  They are still setting up the infrastructure relating to launching this product finding the patients who have and setting them up with a program to be screened and and get started.  this is what happens when you have an orphan drug and a small patient population.

 

Analysts beating on this ticker do not understand the relevence behind this stuff.  they just think BMRN "made 12 million instead of 14 million on this drug in 1Q"-must be underacheiving-drive the price down------DUNCES!

 

They don't even know what they are analyzing half the time! 

 

 

Kutz